How does CAPRA guide decisions about pelvic lymph node dissection?

Higher CAPRA scores correlate with higher nodal risk. Most guidelines recommend extended pelvic lymph node dissection for men with estimated lymph node involvement risk above 5%, roughly corresponding to intermediate and high-risk CAPRA groups.

CAPRA Score Calculator- Free Prostate Cancer Risk Assessment Tool

CAPRA Score Calculator – Free Prostate Cancer Risk Assessment Tool | Super-Calculator.com

JavaScript Required

This CAPRA score calculator requires JavaScript to calculate prostate cancer risk from PSA level, Gleason grade, clinical T-stage, positive biopsy cores, and age at diagnosis. Please enable JavaScript in your browser to use this free prostate cancer risk assessment tool.

Important Medical Disclaimer

This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.

CAPRA Score Calculator

Calculate your Cancer of the Prostate Risk Assessment (CAPRA) score from PSA at diagnosis, Gleason score from biopsy, clinical T-stage, positive biopsy core percentage, and age. Get instant low, intermediate, or high risk classification with biochemical recurrence estimates validated in international cohorts.

PSA at Diagnosis (ng/mL)–

Gleason Score Pattern

Clinical T-Stage

Positive Biopsy Cores (%)–

Age at Diagnosis (years)–

CAPRA Score

–

out of 10 possible points

PSA Points

–

of 4 max

Gleason Points

–

of 3 max

T-Stage Points

–

of 1 max

Core % Points

–

of 1 max

Age Points

–

of 1 max

3-Year Recurrence-Free Survival (Estimated)

–100%

0 – 2

Low Risk

~85-90% RFS

3 – 5

Intermediate Risk

~60-75% RFS

6 – 10

High Risk

~30-50% RFS

CAPRA Variable	Your Value	Points Awarded	Max Possible

RFS = Recurrence-Free Survival after radical prostatectomy. Data from CaPSURE registry and independent validation cohorts.

CAPRA Score	Risk Group	3-Year RFS	Typical Management
0 – 2	Low Risk	~85 – 90%	Active surveillance or monotherapy
3 – 5	Intermediate Risk	~60 – 75%	Definitive treatment, consider multimodal
6 – 7	High Risk	~40 – 55%	Radical prostatectomy + PLND or RT + long ADT
8 – 10	Very High Risk	~25 – 40%	Aggressive multimodal, consider clinical trial

RFS rates are approximate estimates from published validation studies. Individual outcomes vary significantly. PLND = Pelvic Lymph Node Dissection. RT = Radiation Therapy. ADT = Androgen Deprivation Therapy.

Variable	Threshold	Points
PSA at Diagnosis	Below 6 ng/mL	0
PSA at Diagnosis	6 to 10 ng/mL	1
PSA at Diagnosis	10.01 to 20 ng/mL	2
PSA at Diagnosis	20.01 to 30 ng/mL	3
PSA at Diagnosis	Above 30 ng/mL	4
Gleason Score	No grade 4 or 5 (e.g. 3+3)	0
Gleason Score	Secondary grade 4 (3+4)	1
Gleason Score	Primary grade 4 or any grade 5 (4+3, 8-10)	3
Clinical T-Stage	T1 or T2 (organ confined or incidental)	0
Clinical T-Stage	T3a (extraprostatic extension)	1
Positive Biopsy Cores	Below 34% of cores positive	0
Positive Biopsy Cores	34% or more of cores positive	1
Age at Diagnosis	Below 50 years	0
Age at Diagnosis	50 years or older	1
Maximum Total CAPRA Score		10

Reference: Cooperberg MR et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938-1942.

Important Medical Disclaimer

About This CAPRA Score Calculator

This CAPRA score calculator is designed for urologists, radiation oncologists, medical oncologists, and patients seeking to understand prostate cancer recurrence risk before definitive treatment. It computes the Cancer of the Prostate Risk Assessment (CAPRA) score – a validated preoperative risk tool that stratifies newly diagnosed localised prostate cancer into low (0-2), intermediate (3-5), and high (6-10) risk groups based on five clinical variables: PSA level at diagnosis, Gleason grade from diagnostic biopsy, clinical T-stage from examination or imaging, percentage of positive biopsy cores, and age at the time of diagnosis.

The underlying scoring system follows the methodology published by Cooperberg and colleagues from the University of California, San Francisco (UCSF), derived from the CaPSURE database and subsequently validated in independent cohorts from North America, Europe, Australia, and Asia. The calculator applies the published point assignments for each variable – up to 4 points for PSA, up to 3 points for Gleason grade, 1 point each for T3a staging, biopsy core involvement of 34% or more, and age 50 or older – and sums these to produce a score from 0 to 10.

The score breakdown tab shows exactly which variables contribute to the total score, supporting patient-clinician discussions about which risk factors drive the overall classification. The severity reference tab provides published 3-year recurrence-free survival estimates by risk group, and the clinical criteria tab displays the full scoring rubric for quick reference. The CAPRA score is one input into treatment decision-making and should always be considered alongside multidisciplinary specialist assessment, patient values, and comorbidity status.

CAPRA Score Calculator – Complete Guide to Prostate Cancer Risk Stratification

The CAPRA (Cancer of the Prostate Risk Assessment) score is a validated clinical tool used to estimate the risk of prostate cancer recurrence following definitive local treatment. Developed at the University of California, San Francisco (UCSF), the CAPRA score integrates five clinical variables – PSA level at diagnosis, Gleason score, clinical T-stage, percentage of positive biopsy cores, and patient age – into a composite risk estimate ranging from 0 to 10. Clinicians worldwide use this score to guide treatment planning, patient counselling, and decisions about adjuvant therapy after radical prostatectomy or radiation therapy.

Unlike staging systems that rely solely on tumor extent, the CAPRA score accounts for both tumor biology (via Gleason grade) and tumor burden markers (PSA and biopsy core involvement). This multivariable approach produces more accurate predictions of biochemical recurrence, metastasis-free survival, and prostate cancer-specific mortality than any single variable alone. The score is straightforward to calculate from information available at diagnosis, making it practical for routine clinical use across oncology and urology practices globally.

Background and Development of the CAPRA Score

The CAPRA score was developed by Cooperberg and colleagues at UCSF and first published in 2005 using data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database. This registry enrolled patients treated for prostate cancer at over 40 community and academic urology practices across the United States, providing a large and diverse dataset for model development. The original cohort included more than 3,000 patients with clinically localised prostate cancer treated with radical prostatectomy.

The CAPRA score was subsequently validated externally in multiple independent cohorts from North America, Europe, and Australia. A notable validation study published in the Journal of Urology by Cooperberg et al. in 2009 confirmed the score’s predictive accuracy for biochemical recurrence across diverse practice settings. Further validation studies demonstrated the CAPRA score’s utility for predicting outcomes not only after radical prostatectomy but also following external beam radiation therapy and brachytherapy.

The score was designed to be a practical alternative to nomograms that require computational tools. By assigning integer point values to each risk variable, clinicians can calculate the CAPRA score mentally or on paper, then consult published outcome tables. This simplicity has contributed to its widespread adoption in clinical guidelines and multicenter research studies.

CAPRA Score Variables and Scoring System

CAPRA Score Components

CAPRA Score = PSA Points + Gleason Points + T-Stage Points + Biopsy Core Points + Age Points

PSA at Diagnosis

Prostate-specific antigen (PSA) level at diagnosis is the strongest single predictor within the CAPRA model. PSA reflects the secretory activity of prostate epithelial cells and correlates broadly with tumor volume and extracapsular extent. However, PSA alone is insufficient for risk stratification because benign prostatic hyperplasia and prostatitis also elevate PSA, while some aggressive tumors produce little PSA due to poorly differentiated glandular architecture. The CAPRA model assigns up to 4 points for PSA, reflecting the graded increase in recurrence risk across PSA strata.

Gleason Score

The Gleason grading system classifies prostate cancer based on the architectural patterns of tumor glands observed under microscopy. The pathologist assigns a primary grade (most prevalent pattern) and a secondary grade (second most prevalent), summed to produce the Gleason score (range 2 to 10). Within the CAPRA model, the Gleason contribution focuses specifically on the presence of Gleason grade 4 or 5 patterns, which indicate cribriform, fused, or single-cell infiltration – features associated with aggressive biological behavior, lymphovascular invasion, and distant metastasis. The CAPRA Gleason points (0, 1, or 3) reflect the differential impact of primary versus secondary high-grade patterns.

Clinical T-Stage

Clinical T-staging describes the local extent of the primary tumor based on digital rectal examination and imaging findings, before pathological assessment. T1 tumors are not palpable on rectal examination and are discovered incidentally. T2 tumors are palpable and confined to the prostate. T3a tumors have extraprostatic extension beyond the capsule, indicating locally advanced disease. The CAPRA model assigns 1 point for T3a staging, reflecting the substantially higher recurrence risk in men with clinically apparent extraprostatic extension compared to organ-confined disease.

Percentage of Positive Biopsy Cores

The proportion of biopsy cores containing cancer provides an estimate of tumor burden within the prostate. A standard systematic biopsy typically samples 10 to 12 cores from the apex, mid, and base of each lobe. When 34% or more of cores are positive, this indicates more widespread intraprostatic cancer involvement, which correlates with larger tumor volume, higher likelihood of extracapsular extension, and increased risk of seminal vesicle or lymph node involvement. The CAPRA model uses the 34% threshold as a binary variable contributing 1 point, derived from its discriminative value in the CaPSURE dataset.

Age at Diagnosis

Age contributes 1 point for men diagnosed at age 50 or older. Younger men diagnosed with prostate cancer face a longer life expectancy during which residual or recurrent cancer may cause harm, and their cancers may have distinct biological characteristics. However, in the CAPRA model, older age at diagnosis is associated with marginally higher recurrence risk, potentially reflecting competing factors such as longer duration of undetected cancer, or correlation with other adverse features in older patients. Age contributes relatively little to the overall score compared to PSA and Gleason grade.

CAPRA Score Risk Groups and Clinical Outcomes

CAPRA Risk Stratification Groups

Low Risk: 0-2 | Intermediate Risk: 3-5 | High Risk: 6-10

Low Risk (0-2): 3-year recurrence-free survival approximately 85-90%. Active surveillance or definitive monotherapy appropriate.
Intermediate Risk (3-5): 3-year recurrence-free survival approximately 60-75%. Multimodal consideration advised.
High Risk (6-10): 3-year recurrence-free survival approximately 30-50%. Aggressive multimodal treatment typically required.

The three CAPRA risk groups correspond to meaningfully different clinical trajectories. Low-risk men (CAPRA 0-2) have favourable long-term outcomes with either radical prostatectomy or radiation therapy, and some may be appropriate candidates for active surveillance with deferred definitive treatment. Intermediate-risk men (CAPRA 3-5) face a heterogeneous prognosis; some urologists and radiation oncologists stratify this group further into favourable and unfavourable intermediate risk based on the number of intermediate-risk features. High-risk men (CAPRA 6-10) generally require aggressive treatment approaches and have substantially elevated rates of biochemical recurrence, metastasis, and prostate cancer-specific mortality.

Biochemical Recurrence After Radical Prostatectomy

Biochemical recurrence (BCR) after radical prostatectomy is defined as a confirmed PSA level of 0.2 ng/mL or greater on two consecutive measurements after surgery. BCR does not inevitably lead to clinical metastasis or death, but it signals residual cancer activity and identifies men who may benefit from salvage radiation therapy or androgen deprivation therapy. The CAPRA score predicts BCR with a concordance index (c-index) of approximately 0.67 to 0.70 in validation cohorts, which is comparable to or better than the Partin tables and other commonly used nomograms.

Published actuarial data from the CaPSURE registry demonstrate markedly different BCR-free survival curves across CAPRA score groups. Men with CAPRA scores of 0-2 have approximately 85% freedom from BCR at 3 years post-prostatectomy, compared to approximately 60% for scores of 3-5, and approximately 30-40% for scores of 6-10. These differences translate into meaningful clinical decision points regarding the aggressiveness of initial treatment and the threshold for initiating salvage therapy.

CAPRA-S: Post-Surgical Score

An important extension of the original CAPRA score is the CAPRA-S (CAPRA-Surgical) score, which incorporates pathological findings from the radical prostatectomy specimen. CAPRA-S adds three pathological variables to a modified version of the preoperative CAPRA: surgical margin status, seminal vesicle invasion, and lymph node involvement. The CAPRA-S score (range 0 to 12) provides more precise post-surgical risk stratification and is particularly valuable for identifying men most likely to benefit from adjuvant radiation therapy before BCR develops.

The CAPRA-S score has been validated in multiple independent cohorts and demonstrates superior predictive accuracy for BCR, metastasis, and prostate cancer-specific mortality compared to the preoperative CAPRA score alone. Men with CAPRA-S scores of 0-2 have very low BCR rates and may not require adjuvant treatment, while those with scores of 6 or greater have high recurrence probabilities and are strong candidates for immediate adjuvant radiation with or without androgen deprivation therapy.

Key Point: CAPRA vs CAPRA-S

The standard CAPRA score is calculated from information available at diagnosis (preoperative). CAPRA-S incorporates surgical pathology findings and is calculated after radical prostatectomy. Both scores use the same risk group thresholds (low 0-2, intermediate 3-5, high 6-10 or 0-12 for CAPRA-S) but serve different clinical decision points in the treatment pathway.

Comparison with Other Prostate Cancer Risk Tools

Several validated risk stratification tools exist for localised prostate cancer, each with different characteristics and uses. The American Urological Association (AUA) and European Association of Urology (EAU) risk groups classify patients as low, intermediate, or high risk based on PSA, Gleason score, and T-stage, but without the quantitative precision of the CAPRA score. The Partin tables predict pathological stage rather than clinical recurrence. Memorial Sloan Kettering nomograms provide continuous probability estimates for specific outcomes but require computational tools.

The CAPRA score occupies a useful middle ground – more quantitative than categorical AUA/EAU groupings, simpler to calculate than multivariable nomograms, and validated across a broader range of treatment settings. It integrates biopsy core percentage, which most categorical systems omit, providing additional discriminative information particularly useful in men with otherwise similar PSA and Gleason profiles.

Application Across Diverse Populations

Prostate cancer epidemiology, biology, and outcomes vary across ethnic groups and world regions, raising questions about the generalisability of tools derived from predominantly white North American cohorts. The CAPRA score has been studied in African-American, Asian, Hispanic, and European populations with generally consistent predictive performance, though some studies suggest modest differences in the distribution of risk factors and absolute outcome rates between groups.

A validation study in a UK cohort published by Kattan and colleagues demonstrated c-statistics for the CAPRA score comparable to those reported in North American datasets. Studies from Japan and South Korea have similarly reported satisfactory discriminative performance. Overall, the CAPRA score’s relative simplicity and its reliance on universally available clinical variables make it well suited for use across diverse healthcare systems globally.

Limitations of the CAPRA Score

The CAPRA score has several important limitations that clinicians should consider when applying it. First, it was derived before widespread adoption of multiparametric MRI (mpMRI) staging, which can upstage or downstage clinical T-stage compared to digital rectal examination alone. Men staged with contemporary imaging may have different risk profiles than those in the original CaPSURE cohort. Second, the Gleason scoring system itself has undergone revision, with the 2014 International Society of Urological Pathology (ISUP) consensus introducing Grade Groups 1 to 5, which reclassified some Gleason 6 and 7 cancers. Third, the CAPRA score does not incorporate newer prognostic biomarkers such as genomic classifiers (Decipher, Oncotype DX Genomic Prostate Score, Prolaris) or PET imaging findings, which are increasingly available and may refine risk stratification beyond clinical variables alone.

Key Point: Clinical Context is Essential

The CAPRA score is a decision-support tool, not a replacement for expert clinical assessment. Men with the same CAPRA score may have different treatment options based on age, comorbidities, life expectancy, nerve-sparing feasibility, bladder function, and personal values regarding treatment side effects. Always interpret the score within the full clinical picture and refer to specialist oncology and urology care for treatment planning.

Using CAPRA in Treatment Decision-Making

In low-risk disease (CAPRA 0-2), active surveillance is a guideline-supported option for most men, deferring definitive treatment until there is evidence of disease reclassification on surveillance biopsy or imaging. In intermediate-risk disease (CAPRA 3-5), treatment decisions are more nuanced. Many urologists and radiation oncologists further divide this group into favourable intermediate (1 intermediate risk factor) and unfavourable intermediate (multiple intermediate risk factors or Gleason 4+3 pattern). In high-risk disease (CAPRA 6-10), aggressive combined modality treatment is typically indicated, including radical prostatectomy with pelvic lymph node dissection or external beam radiation therapy combined with long-duration androgen deprivation therapy (18 to 36 months).

Interpretation Guide for Patients and Clinicians

When discussing the CAPRA score with patients, it helps to frame the score in terms of relative risk compared to other men with prostate cancer, rather than as an absolute prediction of individual outcomes. A CAPRA score of 2 indicates a favourable risk profile where most men remain free of biochemical recurrence for many years after definitive treatment. A score of 7 indicates substantially elevated risk where most men will experience some evidence of cancer activity within 5 years, though this does not necessarily mean progression to metastasis or death within that timeframe.

Patients should understand that the CAPRA score is one input into treatment decision-making and that treatment effectiveness varies by approach and center experience. Men should be encouraged to discuss their CAPRA score in the context of a multidisciplinary team assessment that includes urological surgery, radiation oncology, and medical oncology perspectives.

Key Point: Shared Decision-Making

Evidence-based risk stratification tools like the CAPRA score support but do not replace shared decision-making. Treatment preferences, quality of life priorities, geographic access to treatment, and individual health literacy all influence treatment choices. The score provides an objective starting point for conversations between patient and clinical team.

Frequently Asked Questions

What does the CAPRA score measure?

The CAPRA score (Cancer of the Prostate Risk Assessment) is a validated tool that estimates the risk of prostate cancer recurrence following definitive local treatment such as radical prostatectomy or radiation therapy. It is calculated from five variables available at diagnosis: PSA level, Gleason score from biopsy, clinical T-stage, percentage of positive biopsy cores, and age. The total score ranges from 0 to 10, with higher scores indicating greater risk of biochemical recurrence and potentially poorer long-term outcomes. The score helps clinicians and patients understand where a particular cancer falls on the risk spectrum and guides decisions about treatment aggressiveness and follow-up intensity.

What is a good CAPRA score?

Lower CAPRA scores indicate more favourable prognosis. A score of 0 to 2 is classified as low risk, associated with approximately 85 to 90% freedom from biochemical recurrence at 3 years after radical prostatectomy. These men generally have excellent long-term outcomes and may be candidates for active surveillance rather than immediate treatment. Scores of 3 to 5 indicate intermediate risk, while scores of 6 to 10 indicate high risk with substantially elevated recurrence probabilities. There is no universally “good” cutoff applicable to all men – the score should be interpreted in the context of individual health, life expectancy, treatment goals, and the full clinical picture.

How is the Gleason score entered into the CAPRA calculator?

The CAPRA model uses the Gleason primary and secondary grades from the diagnostic biopsy. Specifically: if neither the primary nor secondary Gleason grade is 4 or 5, the Gleason contribution is 0 points. If the primary Gleason grade is 4, or if any component is grade 5, the score is 3 points. If the secondary Gleason grade is 4 (and the primary is 3), the score is 1 point. In practice, a Gleason 3+3 = 0 points, Gleason 3+4 = 1 point, Gleason 4+3 = 3 points, and Gleason 8 to 10 (any combination with primary 4 or 5) = 3 points.

What is a positive biopsy core percentage and how do I calculate it?

The percentage of positive biopsy cores is calculated by dividing the number of cores containing cancer by the total number of cores taken, then multiplying by 100. For example, if 4 out of 12 cores are positive, the percentage is 33.3%, which falls below the 34% threshold and scores 0 points. If 5 out of 12 are positive (41.7%), this scores 1 point. Your pathology report should list both the number of positive cores and the total cores sampled, typically recorded as “X of Y cores positive.”

Is the CAPRA score the same as the CAPRA-S score?

No, these are two distinct but related scoring systems. The standard CAPRA score is calculated from preoperative clinical data available at diagnosis, making it applicable to all men with newly diagnosed localised prostate cancer. The CAPRA-S (CAPRA-Surgical) score is calculated after radical prostatectomy and incorporates pathological findings from the surgical specimen, including surgical margin status, seminal vesicle invasion, and lymph node involvement. CAPRA-S is more accurate for post-operative risk stratification and helps guide decisions about adjuvant radiation therapy. This calculator computes the standard preoperative CAPRA score.

How accurate is the CAPRA score?

The CAPRA score has been validated in numerous independent cohorts globally and demonstrates consistent discriminative performance. In radical prostatectomy cohorts, the concordance index (a measure of predictive accuracy analogous to the area under the ROC curve) is typically 0.67 to 0.72 for biochemical recurrence, which is comparable to more complex nomograms. For metastasis-free survival and prostate cancer-specific mortality, the c-index is somewhat lower (0.65 to 0.70), reflecting the greater unpredictability of long-term cancer behavior.

Can the CAPRA score be used after radiation therapy?

Yes. The CAPRA score was validated not only for radical prostatectomy outcomes but also for biochemical recurrence after external beam radiation therapy and brachytherapy. Biochemical recurrence definitions differ: after radical prostatectomy, BCR is defined as PSA 0.2 ng/mL or higher on two measurements; after radiation therapy, BCR is defined by the Phoenix criterion (PSA nadir plus 2 ng/mL). The CAPRA score’s predictive performance for BCR after radiation is similar to that seen after surgery.

Should I be worried if my CAPRA score is high?

A high CAPRA score (6-10) indicates elevated risk of biochemical recurrence and warrants thorough discussion with a specialist urologist or radiation oncologist. However, a high score does not mean that cancer cannot be treated effectively or that outcomes are necessarily poor. Many men with high-risk prostate cancer achieve long-term disease control with aggressive combined modality treatment. The CAPRA score helps clinicians tailor treatment intensity to risk level, so a high score guides more aggressive treatment rather than cause for despair. Consider seeking a multidisciplinary team assessment at a cancer center with experience in high-risk prostate cancer management.

What clinical T-stage should I use if I have had an MRI?

The CAPRA score was developed using clinical T-stage determined by digital rectal examination (DRE). If you have had a multiparametric MRI that identified extraprostatic extension, this information may clinically upstage your disease to T3a even if your DRE was T2. For the CAPRA score, it is most consistent to use the clinical T-stage as assessed by your treating urologist or radiation oncologist, who will integrate both DRE and MRI findings into their staging assessment.

Does the CAPRA score apply to men on active surveillance?

The CAPRA score was validated for predicting recurrence after definitive treatment, not as a tool for monitoring disease during active surveillance. However, it is commonly used at diagnosis to assess whether active surveillance is appropriate (generally recommended for CAPRA 0-2) and may be recalculated if reclassification occurs on surveillance biopsy, showing a higher Gleason grade or more extensive biopsy involvement.

How does CAPRA compare to the D’Amico risk classification?

The D’Amico classification assigns patients to low, intermediate, or high risk based on the worst of PSA, Gleason score, and T-stage. Unlike CAPRA, which provides a continuous score from 0 to 10, the D’Amico system categorises without fine gradation. CAPRA provides finer risk discrimination within D’Amico categories, particularly within the intermediate risk group where outcomes are most heterogeneous. CAPRA also incorporates biopsy core percentage, which D’Amico does not. Studies comparing the two systems consistently show CAPRA has somewhat better discriminative performance.

What PSA level should I use – most recent PSA or PSA at diagnosis?

The CAPRA score uses PSA at the time of prostate cancer diagnosis, not a later measurement taken after biopsy or other procedures. If your PSA was checked multiple times around the time of diagnosis, use the PSA that prompted the biopsy or that was obtained closest to the time of biopsy. PSA can fluctuate slightly between measurements, and transient elevations from prostatitis, instrumentation, or recent sexual activity may artificially inflate a single reading.

Is the CAPRA score affected by the number of biopsy cores taken?

The CAPRA score uses the percentage of positive cores rather than the absolute number, so it is somewhat standardised across different biopsy template sizes. However, the 34% threshold was derived from 12-core systematic biopsy data, which was the standard template when the score was developed. For consistency with the validated scoring system, most clinicians use the total systematic biopsy cores (including targeted) when available.

Can I use this calculator if I have already had surgery?

Yes, the preoperative CAPRA score can still be calculated after surgery using your pre-surgical clinical data (PSA at diagnosis, biopsy Gleason grade, clinical T-stage, core percentage, and age at diagnosis). The score retrospectively characterises your preoperative risk category, which remains relevant for contextualising post-operative findings and informing decisions about adjuvant therapy. Your treating oncologist may also calculate your CAPRA-S score using the surgical pathology data, which provides more precise post-operative risk stratification.

What happens after a high CAPRA score – what are the next steps?

A high CAPRA score (6-10) should prompt referral to or discussion within a multidisciplinary team that includes urological surgery, radiation oncology, and medical oncology. Additional staging investigations are typically recommended for high-risk disease, including bone scan and CT imaging of the abdomen and pelvis, or increasingly, PSMA PET-CT where available. Treatment planning will consider radical prostatectomy with pelvic lymph node dissection versus dose-escalated external beam radiation therapy combined with long-duration androgen deprivation therapy.

Does PSA density or PSA kinetics affect the CAPRA score?

The CAPRA score uses only the absolute PSA value at diagnosis, not PSA density (PSA divided by prostate volume) or PSA kinetics (PSA velocity or doubling time). These additional PSA parameters carry independent prognostic information and are used in some other risk stratification frameworks. However, because PSA density and kinetics require additional measurements, they were not included in the original CAPRA model, which prioritised variables universally available in clinical practice.

How often is the CAPRA score recalculated?

The standard CAPRA score is calculated once at diagnosis using the diagnostic biopsy findings. It may be recalculated if additional biopsy information becomes available – for example, if a man on active surveillance undergoes repeat biopsy showing Gleason grade reclassification or increased core involvement. In general, once definitive treatment has been performed, the CAPRA-S score incorporating surgical pathology provides more relevant post-treatment risk information.

What is biochemical recurrence and what happens if I develop it?

Biochemical recurrence (BCR) refers to a rise in PSA after definitive local treatment indicating residual or recurrent prostate cancer activity. After radical prostatectomy, BCR is defined as a confirmed PSA of 0.2 ng/mL or higher on two consecutive measurements. After radiation therapy, BCR follows the Phoenix definition: PSA nadir plus 2 ng/mL. BCR does not inevitably mean cancer has spread or will cause symptoms. Many men with BCR after surgery benefit from salvage radiation therapy to the prostate bed, which can achieve long-term disease control in a substantial proportion of cases.

Are there genomic tests that can add to CAPRA score information?

Yes. Several commercially available genomic classifiers provide prognostic information complementary to the CAPRA score, particularly for intermediate-risk patients where clinical risk stratification is most uncertain. The Decipher Genomic Classifier uses RNA expression profiling of biopsy or prostatectomy tissue to predict metastasis-free survival. The Oncotype DX Genomic Prostate Score predicts pathological outcomes at prostatectomy. Prolaris measures cell cycle progression gene expression to predict BCR and cancer-specific mortality. Discuss availability and appropriateness with your urologist or oncologist.

How does the CAPRA score guide decisions about pelvic lymph node dissection?

Pelvic lymph node dissection (PLND) at the time of radical prostatectomy provides accurate nodal staging and may have therapeutic benefit in men with intermediate or high-risk disease. The CAPRA score correlates with higher nodal risk at higher scores, though nomograms such as the Briganti nomogram are specifically designed to predict lymph node involvement probability. Most guidelines recommend extended PLND for men with estimated lymph node risk above 5%, roughly corresponding to intermediate and high-risk CAPRA groups.

Is the CAPRA score valid after previous prostate procedures like TURP?

The CAPRA score can generally be applied after transurethral resection of the prostate (TURP) if prostate cancer was subsequently diagnosed, provided that the diagnostic biopsy (or TURP chips) provide Gleason grading, and that a PSA level was obtained before or at diagnosis. If prostate cancer was an incidental finding in TURP chips (clinical T1a or T1b), the T-stage contribution to the CAPRA score is 0 points.

What is the difference between clinical T2a, T2b, and T2c staging?

Clinical T2 staging refers to prostate cancer palpable on digital rectal examination but confined to the prostate gland. T2a indicates involvement of half or less of one lobe. T2b indicates involvement of more than half of one lobe but not both lobes. T2c indicates involvement of both lobes. All T2 substages score 0 points in the CAPRA model, as clinical T2 disease is associated with similar recurrence probabilities regardless of the specific subclassification. Only T3a disease (palpable extraprostatic extension or MRI-identified extracapsular extension) scores 1 point.

Where can I find more information about prostate cancer treatment options?

Reliable information about prostate cancer and treatment options is available from the American Cancer Society (cancer.org), Prostate Cancer Foundation (pcf.org), Prostate Cancer UK (prostatecanceruk.org), and the European Association of Urology Patient Information site (uroweb.org). For clinical guideline summaries, the AUA/ASTRO/SUO guidelines for localised prostate cancer and the EAU Guidelines on Prostate Cancer are freely accessible online. Seeking a second opinion from a prostate cancer specialist is always appropriate when facing complex treatment decisions.

How is CAPRA used in clinical trials?

The CAPRA score is used in prostate cancer clinical trials as an eligibility criterion, stratification factor, and endpoint prediction tool. Many trials restrict enrolment to specific CAPRA risk groups to ensure a homogeneous study population or to target the patients most likely to benefit from experimental interventions. The score is used as a stratification variable at randomisation to balance treatment arms by baseline risk. CAPRA’s consistent validation across international datasets makes it particularly well suited for multicenter and multinational trial use.

What should I bring to my appointment after calculating my CAPRA score?

When discussing your CAPRA score with your urologist or radiation oncologist, bring your diagnostic PSA laboratory result, your prostate biopsy pathology report (showing Gleason scores and core involvement data), any imaging reports (MRI or bone scan), and a list of your current medications. It may help to write down your CAPRA score components and total beforehand so you can discuss which variables contribute most to your risk level and what that means for your treatment options. You are also encouraged to bring a family member or support person to important oncology appointments.

Conclusion

The CAPRA score is a well-validated, widely adopted clinical tool for prostate cancer risk stratification that integrates five routinely available variables into a composite score from 0 to 10. Its three risk groups – low (0-2), intermediate (3-5), and high (6-10) – correspond to meaningfully different prognoses and treatment considerations. The score performs comparably to more complex nomograms in independent validation cohorts across diverse populations worldwide and has been extended to the post-surgical setting through the CAPRA-S modification.

This CAPRA Score Calculator is intended as a clinical decision-support reference for healthcare professionals and an educational resource for patients seeking to understand their risk profile. The score should always be interpreted within the full clinical context, including patient age, comorbidities, life expectancy, treatment preferences, and multidisciplinary team recommendations. For men facing prostate cancer treatment decisions, engagement with specialist urological and oncological care remains the cornerstone of optimal management.